Momenta Pharmaceuticals and Novartis AG unit Sandoz got final approval from a Tennessee federal judge for a $120 million settlement of claims that they tricked regulators into incorporating a patent on their blood thinner Lovenox into a drug testing standard, reported Bloomberg Law.
Judge Waverly D. Crenshaw Jr. gave his blessing May 29 to the agreement, which will hand $40 million to the attorneys representing the class action plaintiffs, after giving it a preliminary nod in January. The deal calls for contributions of $85 million from Sandoz and $35 million from Momenta.
It resolves an antitrust lawsuit accusing the two drugmakers of concealing their pending Lovenox patent application while lobbying the US Pharmacopeial Convention in favor of a testing protocol that would require generic makers to infringe the patent, which was later approved.
The patent covered a method for testing the quality of Lovenox’s active ingredient, used to treat and prevent clots and heart attacks.
The companies must have known what they were doing, because they had just convinced the USPC to condition the testing protocol on the withdrawal of another patent application by nonparty Sanofi-Aventis SA, the original maker of Lovenox, the suit claimed.
The scheme allegedly worked, with the agency approving a protocol that forced generic Lovenox makers to infringe the patent by performing mandated quality tests.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
FCC Votes to Restore Net Neutrality Rules
Apr 25, 2024 by
nhoch@pymnts.com
Apple Rejects Spotify’s Updated App Over In-App Pricing Disclosure
Apr 25, 2024 by
CPI
FCC Set to Reinstate Net Neutrality Rules Today
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI